Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: David Culver who wrote (238)	11/19/1997 8:31:00 PM
From: Sapper	Read Replies (1) \| Respond to of 1185

Here is today's release for those interested: November 19, 1997 NORTRAN PHARMACEUTICALS INC ("NRT-V;NTRDF-L") - Collaborates With Bridge Pharma To Develop Dermal Anesthetics Michael J. A. Walker, Ph.D., Chairman of Nortran Pharmaceuticals Inc. is pleased to announce that it has signed an agreement with Bridge Pharma Inc., a private pharmaceutical research and development company based in Sarasota Florida, to collaborate on the research and development of a series of novel dermal anesthetic compounds. Under the terms of this agreement, Bridge Pharma will manage and conduct studies aimed at selecting a compound for testing in human clinical trials. Nortran will fund these studies and in return Nortran will receive rights to the dermal uses of these compounds and will pay Bridge a 25 percent royalty on Nortran's revenues from this project. "We are pleased to begin this collaboration which is strategically aligned with our technology focus in ion channel pharmacology and our disease focus in pain management," stated Dr. Allen Bain, President of Nortran. "Bridge's knowledge and experience in drug discovery and development will complement Nortran's own such capabilities." Nortran's mission is to capture creativity to discover important new drugs. Nortran has developed a unique system of identifying and nurturing scientific creativity. This system is specifically designed to develop novel approaches to treating diseases where there exists an obvious unmet need. Each project is championed by a world expert. Dr. Aberg, President of Bridge Pharma, Inc., stated "We look forward to working with Nortran in the area of dermal anesthesia, where there is a very obvious need for improved therapy." Prior to founding Bridge Pharma, Dr. Aberg held several senior research and development positions with major pharmaceutical companies including Sepracor Inc., Bristol-Myers Squibb, Ciba-Geigy, and Astra. Dr. Aberg has been involved in successful research and product development resulting in antihistamines, antihypertensives, antiarrhythmics and local anesthetics that are now on the market. Nortran Pharmaceuticals Inc. is a drug discovery company whose focus is pathology targeted small molecules. Nortran's current drugs in development target the ion channels responsible for life-threatening arrhythmias of the heart and for intractable pain. TEL: (604) 822-2278 Sue Milne, Investor Relations TEL: 1-800-330-9928 Nortran Pharmaceuticals Inc. FAX: (604) 822-9578 Internet: nortran.com ______________________________ (c) Corporate Dissemination Services Inc. All rights reserved.